BioInvent International (BINV) Q2 2026 earnings summary

Executive summary

• Achieved significant clinical milestones in Q2 2026, including strong efficacy data for BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL, with results presented at ASCO and EHA 2026.

• BI-1808 received FDA Fast Track Designation for ovarian cancer after the period, validating its development strategy and potential in a high unmet need area.

• Two successful KOL events highlighted the clinical and commercial potential of BI-1808 and BI-1206 in oncology.

Financial highlights

• Q2 2026 net sales were SEK 12.8 million, down from SEK 198.1 million in Q2 2025, mainly due to a one-time royalty sale in the prior year.

• Profit/loss after tax for Q2 2026 was SEK -122.9 million, compared to SEK 38.8 million in Q2 2025; for H1 2026, SEK -242.1 million vs. SEK -77.8 million in H1 2025.

• Liquid funds and current investments at June 30, 2026, were SEK 340.8 million, down from SEK 797.5 million a year earlier.

• Cash flow from operating activities for H1 2026 was SEK -244.8 million.

Outlook and guidance

• Additional data from the BI-1808 plus pembrolizumab expansion cohort in ovarian cancer expected in H2 2026.

• Initiation of BI-1808 Phase 2a triplet study in ovarian cancer and first readout from BI-1206 plus pembrolizumab in NSCLC and uveal melanoma anticipated in H2 2026.

• Company is financed into late Q1 2027 but faces material uncertainty regarding future financing, with efforts ongoing to secure funding in H2 2026.